Please login to the form below

Not currently logged in
Email:
Password:

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

Subhanu Saxena has left Novartis to join India-based generics company Cipla as its new CEO.

Saxena was previously head of global product strategy and commercialisation at Novartis, where he was also part of the Swiss pharma giant's executive committee, and will take up his new position from February 1, 2013.

Prior to this most recent position at Novartis, Saxena was CEO and country president of Novartis UK.

He also has wide non-healthcare experience, working with companies such as Citicorp, the Boston Consulting Group and PepsiCo across markets in Europe, North America, Africa and Asia.

Cipla's chair Dr Yusuf Hamied said: “We are delighted to have found such a good match for Cipla in Subhanu. Cipla has a strong vision for the future. I am confident Subhanu will build on Cipla's core values to deliver the next phase of growth, competitiveness and return on shareholder value.”

Saxena joins at a time of growth for Cipla, with the company recently announcing plans to expand its footprint in Africa.

Cipla has also been busy challenging big pharma patents, and in September won a four-year battle to market its own version of Roche's cancer drug Tarceva (erlotinib). The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.

26th November 2012

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics